NEW YORK (TheStreet) -- CHANGE IN RATINGS
Apple (AAPL) was upgraded at UBS to buy from neutral. Driven by stabilizing iPad gross margins, emergence of China Mobile and further new product rollout, UBS said. $650 price target.
Cobalt (CIE) was downgraded at Credit Suisse to neutral from outperform. $26 price target. Company is seeing lower production results, Credit Suisse said.
3D Systems (DDD) was initiated with an outperform rating at FBR Capital Markets. $85 price target. Company should see better penetration rates and higher customer demand, FBR Capital Markets said.
Fortinet (FTNT) was upgraded at Bank of America/Merrill Lynch to buy from neutral. $24 price target. Stock appears oversold following the recent CFO resignation, which appears to be for personal reasons, BofA/Merrill said.
Franklin Electric (FELE) was downgraded at Wedbush to neutral. Valuation call, based on a $43 price target, Wedbush said.
Winthrop Realty Trust (FUR) was upgraded to buy at TheStreet Ratings.
Fusion-io (FIO) was downgraded at UBS to neutral from buy. Concern about management change and competitive environment, UBS said. $11 price target.
HollyFrontier (HFC) was upgraded at Bank of America/Merrill Lynch to buy. $60 price target. Company has lagged its peers during a seasonal rebound, BofA/Merrill said.
Imax (IMAX) was downgraded at Goldman Sachs to neutral from buy. Valuation call, based on a $30 price target, Goldman Sachs said.
Micron (MU) was initiated with a buy rating at Needham. $30 price target. Stocks should see multiple expansion in the coming quarters, Needham said.
[Read: Apple, China Mobile: It's Here]
Myriad Genetics (MYGN) was downgraded at JMP Securities to market perform from outperform. Company could face lower reimbursement levels, JMP Securities said.
Servotronics (SVT) was downgraded to hold at TheStreet Ratings.
Total System (TSS) was upgraded at Robert Baird to outperform from neutral. $38 price target. Organic revenue growth can re-accelerate in the coming years, Baird said.
Westar Energy (WR) was upgraded at Goldman Sachs to buy from neutral. $34 price target. Company is seeing lower costs and can deliver above-average dividend growth, Goldman said.
[Read: Bad Credit Card Rewards Programs]
Stock Comments / EPS Changes
Abbvie (ABBV) was added to the Conviction Buy List at Goldman Sachs. Company has an attractive pipeline, with multiple potential catalysts, Goldman said. $60 price target.
Chipotle (CMG) estimates, price target were raised at Sterne Agee. Shares are now seen reaching $603. Estimates were also increased as the catering menu should help drive growth, Sterne Agee said. Buy rating.
Forest Labs (FRX) price target, EPS estimates were increased at UBS. Restructuring delivered $500 in cost savings and M&A activity in the short term, UBS said. $57 price target and neutral rating.
Pfizer (PFE) was cut from the Conviction Buy List at Goldman Sachs. Valuation call, based on a $35 price target, Goldman said.
Valeant (VRX) price target was increased at UBS. Expectation of smaller accretive deals, UBS said. $125 price target and buy rating.